Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Fasinumab in Healthy Japanese and Caucasian Subjects
NCT02516618Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2015
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fasinumab in osteoarthritis (OA) (5 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Treatment Emergent Adverse Events. Started Jul 2015; status: completed.
02
Drugs
fasinumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02516618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02516618.